ArticleVeterinary research2025
Galectin-3: a novel antimicrobial host factor identified in goat nasal mucus.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From models to medicine: systematic development and evaluation of animal models forFrontiers in immunology · 2026Review
- The Causal Effects of Inflammation and Coagulation-Related Biomarkers on Sepsis-Related Complications: A Mendelian Randomization Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory infections caused by pathogenic bacteria pose a rapidly growing public health threat. The nasal mucus layer serves as the first line of defense against pathogen invasion; however, in nasal mucus, the antimicrobial components and their underlying mechanisms remain unclear. Here, we collected nasal mucus from goat nasal mucosal explant models and identified significant antimicrobial activity in the total protein fraction. Subsequent fractionation indicated that proteins < 30 kDa exhibited the most potent bactericidal activity. Nano LC-ESI-MS/MS analysis identified galectin-3 as a key protein with potent activity against Gram-positive bacteria, particularly Streptococcus suis (S. suis). Galectin-3 targeted teichoic acids on the bacterial surface, disrupting membrane integrity. Additionally, it inhibited the synthesis of three critical bacterial proteins: enoyl-ACP reductase (FabK), carbamate kinase (CK), and small ribosomal subunit protein uS2 (rpsB), thereby destroying bacterial growth and metabolism. In the murine nasal infection model, galectin-3 accelerated the clearance of S. suis and alleviated pathological damage caused by the infection. Taken together, our findings provide the first evidence of the direct antimicrobial action of galectin-3 in nasal mucus and elucidate its mechanisms involving bacterial membrane disruption and inhibition of key metabolic proteins. These results highlight galectin-3 as a promising therapeutic target for S. suis infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.